Vaccination Research · 2016 · pp. e3–e5 · e-ISSN 2771-750X

Current Status of Human Immunodeficiency Virus Vaccines

Daniela Sosa, Rahul Dev Jayant, Ajeet Kaushik, Madhavan Nair

DOI: https://doi.org/10.17140/vroj-1-e002 · Published 2016-07-18 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2016 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Highly Active Antiretroviral Therapies (HAARTs) have been developed to treat HIV+ individuals, increasing the quality and quantity of life of many HIV+ patients. Despite these effective strategies, human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) epidemic continues to uphold globally with 39 million infected individuals. 1 However, the HIV retrovirus integrates into the (cluster of differentiation 4) CD4+ cells’ genomes where it can persist for years in a latent stage forming HIV reservoirs throughout the body.2 Due to these reservoirs, infected individuals need to be under treatment for the rest of their lives, as HAARTs cannot fully cure HIV.3,4 As a result, preventive strategies have now been introduced in the plan to completely eradicate the HIV/AIDs endemic.5 Effective preventative strategies that decrease bodily fluids transmissions like the usage of condoms, sterile needles, abstinence, monogamy between uninfected individuals, and voluntary testing have been developed. The development of vaccines as preventative and treatment strategies against HIV has been proposed to aid in the eradication of this disease.5,6 Typically, vaccines have been successful in the disappearance of past endemics such as polio and small pox. Vaccine development for HIV began in the 1980’s.1 Two types of vaccines have been proposed: those as protection against acquisition of HIV-1 and those as treatment to cure HIV in conjunction with HAART.1,5

Acknowledgement

The authors acknowledge financial support from NIH grants RO1-DA040537, RO1-DA037838, RO1-DA042706-A and RO1- DA027049. Authors would like to acknowledge Institute of NeuroImmunune Pharmacology (INIP) research facility and support.

Competing Financial Interests

The authors declare no competing financial interests.

References

  1. SheetsRLZhouTKnezevicI. Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned: A review from a regulatory perspective. Biologicals. 2016; 44(2): 73-89. doi: 10.1016/j.biologicals.2015.10.00410.1016/j.biologicals.2015.10.004 https://doi.org/10.1016/j.biologicals.2015.10.004
  2. NairMJayantRDKaushikASagarV. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016; 103: 202-217. doi: 10.1016/j.addr.2016.02.00810.1016/j.addr.2016.02.008 https://doi.org/10.1016/j.addr.2016.02.008
  3. JayantRDAtluriVSAgudeloMSagarVKaushikANairM. Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomedicine. 2015; 10: 1077-1093. doi: 10.2147/IJN.S7651710.2147/ijn.s76517 https://doi.org/10.2147/ijn.s76517
  4. KaushikAJayantRDNairM. Advancements in Nano-enabled therapeutics for neuroHIV management. Int J Nanomedicine. 2016; 11: 1-9
  5. AutranB. Toward a cure for HIV-Seeking effective therapeutic vaccine strategies. Eur J Immunol. 2015; 45(12): 3215-3221. doi: 10.1002/eji.20154551310.1002/eji.201545513 https://doi.org/10.1002/eji.201545513
  6. Vaccines. AIDS 2016. 2016. Web site. https://www.aids.gov/hiv-aids-basics/prevention/prevention-research/vaccines/. Accessed July 13, 2016
  7. Excler J-L, Robb ML, Kim JH. Prospects for a globally effective HIV-1 vaccine. Vaccine. 2015; 33: D4-D12. doi: 10.1016/j.vaccine.2015.03.059 https://doi.org/10.1016/j.vaccine.2015.03.059
  8. MoodieZJanesHHuangY. New clinical trial designs for HIV vaccine evaluation. Curr Opin HIV AIDS. 2013; 8(5): 437-442. doi: 10.1097/COH.0b013e328363d46a10.1097/coh.0b013e328363d46a https://doi.org/10.1097/coh.0b013e328363d46a
  9. DayTAKublinJG. Lessons learned from HIV vaccine clinical efficacy trials. Curr HIV Res. 2013; 11(6): 441-449. doi: 10.2174/1570162X11311666005110.2174/1570162x113116660051 https://doi.org/10.2174/1570162x113116660051
  10. NAM AIDS map. The RV144 trial. 2009. Web site. http://www.aidsmap.com/The-RV144-trial/page/2028003/. Accessed July 13, 2016
  11. GrayGELaherFLazarusEEnsoliBCoreyL. Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016; 17: 104-109. doi: 10.1016/j.coviro.2016.02.01010.1016/j.coviro.2016.02.010 https://doi.org/10.1016/j.coviro.2016.02.010
  12. Chun T-W, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015; 16(6): 584- 589. doi: 10.1038/ni.3152 https://doi.org/10.1038/ni.3152
  13. ConnollyNCWhitesideTLWilsonCKondraguntaVRinaldoCRRiddlerSA. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol. 2008; 15(2): 284-292. doi: 10.1128/CVI.00221-0710.1128/cvi.00221-07 https://doi.org/10.1128/cvi.00221-07
  14. MacatangayBJRiddlerSAWheelerND. Therapeutic vaccination with dendritic cells loaded with autologous HIV type 1-infected apoptotic cells. J Infect Dis. 2016; 213(9): 1400-1409. doi: 10.1093/infdis/jiv582 Page e510.1093/infdis/jiv582 https://doi.org/10.1093/infdis/jiv582